Colitis
Methodology & AI Transparency ⓘ
Colitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Colitis is an ICD-10-CM indexed diagnosis (K52.9) within IBS, Crohn, Colitis & Bowel Disorders.
- 2 Real-world patient consensus: Mapped to IBS, Crohn, Colitis & Bowel Disorders under ICD-10-CM K52.9 for Colitis clinical workups.
- 3 Typical cash cost range: Workup highlights for Colitis (K52.9): targeted soluble fiber/low-FODMAP in Colitis (K52.9: dietary titration).
- 4 Top reported side effects / signs: Objective lab/clinical target for Colitis: hs-CRP, CBC & in Colitis (K52.9: Ferritin) (Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9)) and Fecal Calprotectin [Colitis K52.9].
Ask our AI Specialists anything about Colitis
What Is Colitis?
Colitis is an ICD-10-CM indexed diagnosis (K52.9) within IBS, Crohn, Colitis & Bowel Disorders. Clinical evaluation centers on targeted soluble fiber/low-FODMAP in Colitis (K52.9: dietary titration) alongside serial hs-CRP, CBC & in Colitis (K52.9: Ferritin) tracking (Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in ibs, ibd & colon, Colitis (K52.9) involves intestinal microbiome dysbiosis [Colitis K52.9]. progression correlates with shifts in hs-CRP, CBC & in Colitis (K52.9: Ferritin) (Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9)).
Common Symptoms & Clinical Signs
- • Presentation of Colitis (K52.9): post-meal abdominal distension, in Colitis (K52.9: gas bloating, or)
- • Secondary Colitis clinical sign: rectal bleeding, nocturnal in Colitis (K52.9: bowel movements, or)
- • Symptom flares in Colitis correlating with hs-CRP, CBC & in Colitis (K52.9: Ferritin) deviation outside Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9)
- • Functional ibs, ibd & colon impact requiring targeted soluble fiber/low-FODMAP in Colitis (K52.9: dietary titration) evaluation (K52.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Colitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K52.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | IBS, Crohn, Colitis & Bowel Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP, CBC & in Colitis (K52.9: Ferritin) | Normal hemoglobin; hs-CRP < 1.0 mg/L (K52.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fecal Calprotectin [Colitis K52.9] | < 50 mcg/g (K52.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Tissue Transglutaminase IgA in Colitis (K52.9: (tTG-IgA)) | Negative (celiac rule-out) (K52.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Colitis
Treatment selection for Colitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Colitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic: What a 2,639-Participant Study Found Overall (N = 2,639; 3 mg of plecanatide [n = 877]; 6 mg of plecanatide [n = 877]; and placebo [n = 885]), CSBM responder rates were significantly greater with 3 mg of plecanatide and 6 mg of plecanatide vs placebo in subgroups... Clinical and translational gastroenterology • 2023-07-01 • Phase III Randomized Trial | N = 2,639 | 96/100 | PMID 37162147 ↗ |
| New Insights on Benefits and safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor: What a 1,139-Participant Study Found Tofacitinib was efficacious in patients with UC regardless of prior TNFi failure status. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-03-15 • Phase III Randomized Trial | N = 1,139 | 96/100 | PMID 33684552 ↗ |
| New Insights on Long-term safety and real-world benefits of filgotinib for the treatment of: What a 250-Participant Study Found Filgotinib induced and maintained symptomatic full symptom relief and improved HRQoL over 4 years. Alimentary pharmacology & therapeutics • 2024-09-15 • Phase III Randomized Trial | N = 250 | 93/100 | PMID 39086130 ↗ |
| New Insights on Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events: What a 787-Participant Study Found Patients receiving etrasimod demonstrated no increased risk of infection. Journal of Crohn's & colitis • 2024-10-15 • Phase III Randomized Trial | N = 787 | 93/100 | PMID 38700040 ↗ |
| Can This Approach Help? Inside the Latest Research on Therapeutic Modulation of IL-6/STAT-3 and Nitric Oxide by Fenofibrate in Patients Fenofibrate may represent a promising add-on therapy in patients with mild-to-moderate UC by modulating inflammation and improving QoL. Pharmacotherapy • 2025-12-15 • Phase III Randomized Trial | N = 60 | 88/100 | PMID 41330887 ↗ |
Colitis Patient Community & “People Like Me” Threads
Filter Colitis community threads and patient logs by age, biological sex, dosage, and treatment duration.